Results of COLUMBUS Part 2: A phase 3 trial of encorafenib (ENCO) plus binimetinib (BINI) versus ENCO in BRAF-mutant melanomaReinhard Dummer, Keith T. Flaherty, Naoya Yamazaki et al.|Annals of Oncology|2017Cited by 40
Overall survival in COLUMBUS: A phase 3 trial of encorafenib (ENCO) plus binimetinib (BINI) vs vemurafenib (VEM) or enco in <i>BRAF</i>-mutant melanoma.Reinhard Dummer, Keith T. Flaherty, Paolo A. Ascierto et al.|Journal of Clinical Oncology|2018Cited by 30
Hospitalization Rates in COLUMBUS Part 1: A Phase 3 Trial of Encorafenib (ENCO) Plus Binimetinib (BINI) Versus Vemurafenib (VEM) or ENCO in BRAF-Mutant MelanomaAna Arance, Keith T. Flaherty, Reinhard Dummer et al.|Annals of Oncology|2017Cited by 10
Quality-of-life (QoL) in COLUMBUS part 1: A phase 3 trial of encorafenib (ENCO) plus binimetinib (BINI) versus vemurafenib (VEM) or ENCO in braf-mutant melanomaHelen Gogas, Keith T. Flaherty, Reinhard Dummer et al.|Annals of Oncology|2017Cited by 3
Adverse events of special interest in the phase 3 COLUMBUS study.Helen Gogas, Keith T. Flaherty, Reinhard Dummer et al.|Journal of Clinical Oncology|2018Cited by 3